Graphite Bio Inc. (GRPH)
3.18
-0.09 (-2.75%)
At close: Mar 21, 2024, 8:00 PM
-2.75% (1D)
| Bid | n/a |
| Market Cap | 185.19M |
| Revenue (ttm) | 10.24M |
| Net Income (ttm) | -117.36M |
| EPS (ttm) | -15.33 |
| PE Ratio (ttm) | -0.20743639921722112 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 299,406 |
| Avg. Volume (20D) | 40,955 |
| Open | 3.20 |
| Previous Close | 3.27 |
| Day's Range | 3.05 - 3.23 |
| 52-Week Range | 3.05 - 29.82 |
| Beta | 0.20 |
About GRPH
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a pro...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol GRPH
Website https://www.graphitebio.com